Ypsomed
Company Snapshot
Company Overview
Ypsomed develops and manufactures injection pens for global pharmaceutical and biotech companies. The company operates in two segments: Delivery Devices and Diabetes Direct Business.
The Diabetes Direct business sells and trades devices for self-monitoring blood glucose levels, infusion pumps, accessories, and other day-to-day items for people with diabetes. It offers insulin pumps, injection systems, and pen needles for treating diabetes, growth disorders, infertility, and other therapeutic areas under the mylife Diabetes Care brand. These products are marketed directly to diabetes patients, doctors, specialist personnel, or health insurance providers.
Ypsomed markets its products through biotech and pharmaceutical partners, its distribution network, and independent distributors.
Financial Highlights (FY 2024)
This information is available for BCC Research members only.
Ypsomed In News
Company's Business Segments
- Diabetes Care : Ypsomed Diabetes Care offer a Modular, Customisable solution for a Diabetes Therapy Management that is both Flexible, Expandable.
- Delivery Systems : Ypsomed Delivery Systems provides a complete range of Technologies, Services for reliable and user-friendly Injection Systems as well as Digital Health Solutions for Self-medication.
Applications/End User Industries
- Diabetes
- Therapeutics
- Healthcare
- Hospitals
- Pharmacies
- Retail
- Clinics
- Insulin
- Injection System
- Infusion Systems
- Self-Medication
- Liquid Drugs
- Digital Health Solutions
